
Amgen (AMGN) Stock Forecast & Price Target
Amgen (AMGN) Analyst Ratings
Bulls say
Amgen's positive outlook is supported by a robust commitment to research and development, with management guiding for over 20% R&D growth in 2025 compared to 2024, an increase from earlier expectations. The significant sales growth of Uplizna, showing a 58% increase in June 2025 compared to the previous quarter and a 40% jump from the same period in 2024, further underscores the company’s strong market position and successful product launches. Additionally, the continuation of pipeline advancements suggests a favorable scenario for multiple expansion, with an expected EV/2026E EBITDA of approximately 13 times, indicating strong potential for future earnings growth.
Bears say
Amgen's financial outlook is concerning due to its reliance on a narrow range of flagship products, which face increasing competition and potential market saturation, particularly as patent expirations loom. Despite recent acquisitions and product launches aimed at diversifying its portfolio, the company's revenue growth has been stunted, prompting worries about its ability to maintain profitability in the long term. Additionally, the rise of biosimilars and the impact of regulatory pressures on pricing strategies further exacerbate the challenges Amgen faces in sustaining its competitive edge within the biotechnology sector.
This aggregate rating is based on analysts' research of Amgen and is not a guaranteed prediction by Public.com or investment advice.
Amgen (AMGN) Analyst Forecast & Price Prediction
Start investing in Amgen (AMGN)
Order type
Buy in
Order amount
Est. shares
0 shares